Composition for preventing and improving Alzheimer's disease and preparation method thereof

Abstract

The invention belongs to the technical field of biological pharmacy, and particularly relates to a composition for preventing and improving Alzheimer's disease and a preparation method thereof. The composition is prepared by the following method: (S1) adding phosphatidylserine, an emulsifier and walnut peptide into walnut sauce to obtain an oil phase; (S2) dissolving xylitol, whole milk powder and taurine in water, and slowly adding the oil phase in the homogenizing process to obtain a mixed solution; and (S3) dissolving a stabilizer in water to obtain a stabilizer solution, adding the stabilizer solution into the mixed solution, adding water to a constant volume, uniformly mixing, and homogenizing to obtain the composition for preventing and improving the Alzheimer's disease. The precipitation phenomenon caused by the Maillard reaction of walnut peptides is avoided, the antioxidant components in the walnut sauce can prevent phosphatidylserine from being oxidized and degraded, the quality problems of oxidative rancidity, fat floating and layering and the like of the walnut sauce are solved, the stability of the composition is improved, the shelf life of the product is prolonged, and the competitiveness of the product is improved.

Description

Technical Field

[0001] This invention belongs to the field of biopharmaceutical technology, and in particular relates to a composition for preventing and improving Alzheimer's disease and its preparation method. Background Technology

[0002] Alzheimer's disease (AD) is a primary, progressive, and fatal neurodegenerative disease with insidious onset and unknown cause. It is a general term for early-onset dementia and late-onset dementia. In my country, one-third of the population aged 85 and over suffers from Alzheimer's disease. Alzheimer's patients experience varying degrees of impairment in cognitive function, social skills, and self-care abilities, placing a significant burden on their families and society. The cost of caring for an Alzheimer's patient is 14 times that of a cancer patient, and currently, there is no cure through medication; prevention and management remain the best approaches.

[0003] Phosphatidylserine (PS) is a naturally occurring acidic phospholipid found in cell membranes, particularly abundant in brain nerve cells (accounting for 70% of the total phospholipids in nerve tissue). It plays an important role in cognitive function, mood regulation, and brain health.

[0004] Walnut peptides are produced using bioengineering-based targeted enzymatic hydrolysis technology, which breaks down large protein molecules into smaller peptides. Walnut peptides are known to improve memory, digestion, and immunity, regulate mood, promote restful sleep, and possess strong antibacterial properties.

[0005] Walnut butter is made from paper-shelled walnuts through soaking, peeling, roasting to extract oil, and grinding. It is rich in unsaturated fatty acids, as well as minerals such as calcium, iron, and zinc, vitamin E, B vitamins, and polyphenols (such as ellagic acid). It is believed to enhance brain function and memory, promote intellectual development, and have anti-aging effects.

[0006] Patent application number CN201811648298.1 discloses a composition with neuroprotective effects, mainly comprising: Gastrodia elata extract and walnut peptide. The preparation method includes extraction, filtration, concentration, and drying. The composition exhibits good free radical scavenging activity, can enhance memory, promote nervous system recovery, and protect nerve tissue. It can be developed into a food, health food, or pharmaceutical for brain health and for the prevention, improvement, or treatment of Alzheimer's disease, Parkinson's disease, and other related neurological diseases.

[0007] Plant protein beverages made from walnut paste, walnut peptides, and phosphatidylserine are prone to non-enzymatic browning during high-temperature sterilization, forming flocculent precipitates that make the oral solution cloudy. They are also susceptible to quality problems such as oxidative rancidity and fat stratification, creating the illusion of product quality issues. Summary of the Invention

[0008] To address the aforementioned problems, this invention proposes a preparation method that produces a composition for preventing and improving Alzheimer's disease that does not undergo non-enzymatic browning, has stable quality, and a long shelf life.

[0009] A method for preparing a composition for preventing and improving Alzheimer's disease includes the following steps: (S1) Add 0.2-0.25 kg of phosphatidylserine, 0.12 kg of emulsifier and 0.40-0.45 kg of walnut peptide to 2.70 kg of walnut paste preheated to 40-45℃, mix well to obtain the oil phase; (S2) Dissolve 4 kg of xylitol, 4 kg of whole milk powder and 0.20-0.25 kg of taurine in 45 L of water, mix well and homogenize. During the homogenization process, slowly add the oil phase to obtain a mixed solution. (S3) Dissolve 0.15g of stabilizer in 15L of water preheated to 75°C to obtain a stabilizer solution, wherein the stabilizer includes carrageenan. Add the stabilizer solution to the mixed solution, add water to make up to 135L, mix well and homogenize to obtain a composition for preventing and improving Alzheimer's disease.

[0010] The walnut paste was passed through a 120-mesh sieve.

[0011] The walnut paste is a cold-pressed walnut paste made at low temperatures.

[0012] The unsaturated fatty acid chains of phosphatidylserine make it susceptible to oxidative damage, easily leading to rancidity in emulsions. Walnut butter, rich in vitamin E, a fat-soluble antioxidant, can intercalate into the lipid bilayer of phosphatidylserine, terminating free radical chain reactions by providing hydrogen atoms and thus delaying the oxidative rancidity of the unsaturated fatty acid chains. Walnut butter also contains ellagic acid, flavonoids, and other antioxidant compounds that neutralize hydroxyl radicals in the emulsion, reducing the oxidative damage to phosphatidylserine. Furthermore, the abundant unsaturated fatty acids in walnut butter can interact hydrophobically with the fatty acid chains of phosphatidylserine, forming a physical barrier and reducing the oxidative damage to phosphatidylserine from air.

[0013] Walnut peptides have good compatibility with the proteins in walnut paste. Through the dispersing effect of emulsifiers, walnut peptides can be evenly distributed in walnut paste.

[0014] The researchers of this invention discovered that using xylitol as a sweetener and adding a small amount of taurine at a high concentration can prevent precipitation caused by non-enzymatic browning of walnut paste and walnut peptides during high-temperature sterilization, and avoid Maillard reaction between walnut peptides and lactose in whole milk powder.

[0015] Whole milk powder typically contains no less than 37% lactose. As a reducing sugar, lactose's aldehyde group readily condenses and polymerizes with the amino group of walnut peptides under heating (≥85℃), ultimately forming brown macromolecules such as melanoidins. Their hydrophobic structure easily aggregates with oils or proteins in the emulsion, forming visible flocculent matter. This affects the stability of the composition and reduces the activity of the walnut peptides.

[0016] Xylitol is a pentose sugar alcohol whose molecule does not contain an aldehyde or ketone group (i.e., no reducing terminator), and therefore cannot undergo the carbonyl-amino condensation required for the Maillard reaction with free amino groups in peptide chains (such as the ε-amino group of lysine). Taurine also lacks a reducing terminator and does not directly participate in the carbonyl-amino condensation of the Maillard reaction. Xylitol and taurine bind to the free amino groups of walnut peptides, occupying the reaction sites of lactose (reducing sugar) on the walnut peptides, thus physically blocking the reaction and preventing the browning of walnut peptides and lactose during high-temperature sterilization. Taurine can also specifically bind to dicarbonyl compounds generated in the Maillard reaction, blocking the Maillard reaction from proceeding.

[0017] The stabilizer also includes sodium tripolyphosphate, wherein the weight ratio of sodium tripolyphosphate to carrageenan in the stabilizer is 1:4.

[0018] Sodium tripolyphosphate can chelate with calcium, iron, and zinc ions in walnut butter, preventing the Maillard reaction catalyzed by metal ions.

[0019] In step (S3), 0.12 kg of carrageenan is dissolved in 15 L of water preheated to 75 °C. After dissolution, 0.03 kg of sodium tripolyphosphate is added and stirred until homogeneous to obtain a stabilizer solution.

[0020] (S3) Dissolution time is 30-40 min, and stirring speed is 120 rpm.

[0021] (S1) The emulsifier includes mono-, mono-, and diglycerides of fatty acids and sucrose fatty acid esters, with a weight ratio of 1:1.

[0022] Mono- and diglycerides of fatty acids can enhance the dispersion of the oil phase in emulsions, inhibit lipid crystallization, and prevent oil separation in walnut butter; sucrose fatty acid esters can enhance the interfacial adsorption of proteins and delay the oxidative aggregation of walnut peptides.

[0023] In (S1), a high-shear emulsifier is used for mixing, with a stirring speed of 5000-8000 rpm and a stirring time of 10-15 min.

[0024] (S2) The homogenization pressure is 25 MPa, and homogenization is performed three times. (S3) The homogenization pressure is 20 MPa, and homogenization is performed twice.

[0025] The method for preparing the composition for preventing and improving Alzheimer's disease includes the following steps: (S1) Add 0.21 kg of phosphatidylserine, 0.12 kg of emulsifier and 0.42 kg of walnut peptide to 2.70 kg of walnut paste preheated to 40-45℃, mix well to obtain the oil phase; (S2) Dissolve 4 kg of xylitol, 4 kg of whole milk powder and 0.21 kg of taurine in 45 L of water, mix well and homogenize. During the homogenization process, slowly add the oil phase to obtain a mixed solution. (S3) Dissolve 0.03 kg of sodium tripolyphosphate and 0.12 kg of carrageenan in 15 L of water preheated to 75 °C to obtain a stabilizer solution. Add the stabilizer solution to the mixed solution, add water to make up to 135 L, mix again and homogenize to obtain a composition for preventing and improving Alzheimer's disease.

[0026] A composition for preventing and improving Alzheimer's disease, prepared by the preparation method according to any one of claims 1-8.

[0027] The composition for the prevention and improvement of Alzheimer's disease is used in the preparation of food or medicine for Alzheimer's disease.

[0028] The combination of walnut peptides and taurine can significantly inhibit the activity of BACE1. BACE1 is an aspartic protease, officially known as β-site amyloid precursor protein cleavage enzyme 1. BACE1 is a key enzyme in the metabolism and breakdown of amyloid precursor protein, which leads to the formation of β-amyloid protein. Excessive accumulation of β-amyloid protein in the brain is a typical pathological feature of Alzheimer's disease. Therefore, inhibiting BACE1 activity can directly reduce the formation of β-amyloid protein.

[0029] Walnut peptides, taurine, and phosphatidylserine exhibit synergistic effects in the treatment and prevention of Alzheimer's disease. Walnut peptides can reduce the cleavage of β-amyloid precursors, inhibit BACE1 activity, and, in combination with taurine, indirectly inhibit the oxidative stress activation pathway of BACE1 by scavenging oxygen free radicals. Taurine also improves neuronal function. Phosphatidylserine can stimulate the release of dopamine-like substances, increase the production of the neurotransmitter acetylcholine, enhance glucose metabolism in the brain, reduce cortisol secretion, and even affect the metabolic activity of steroid-loaded substances on brain cell membranes, altering cell membrane fluidity.

[0030] The composition of the present invention for preventing and improving Alzheimer's disease has the following advantages: The oral solution of this invention can avoid the formation of flocculent precipitate due to non-enzymatic browning between peptides and lactose, and has good quality stability. The oral solution of this invention can improve the stability of phosphatidylserine in emulsions and prevent phosphatidylserine from oxidative rancidity. Walnut peptides, taurine, and phosphatidylserine have a synergistic effect, which can inhibit BACE1 activity through multiple dimensions such as direct enzyme inhibition, anti-oxidation, and signaling pathway synergy, thereby improving Alzheimer's disease and reducing the risk of Alzheimer's disease. Attached Figure Description

[0031] Figure 1 This is a bar chart showing the content of APP, Aβ1-42 and BACE1 protein in the hippocampus of rats in Experiment Example 4 of this invention. Detailed Implementation

[0032] The present invention will be described in detail below with reference to the accompanying drawings and embodiments. Example 1

[0033] (S1) Add 0.2 kg of phosphatidylserine, 0.06 kg of mono- and diglycerides of fatty acids, 0.06 kg of sucrose fatty acid esters, and 0.45 kg of walnut peptides to 2.70 kg of walnut paste preheated to 40-45℃, mix well, and obtain the oil phase; (S2) Dissolve 4 kg of xylitol, 4 kg of whole milk powder, and 0.25 kg of taurine in 45 L of water, mix well, and homogenize. During homogenization, slowly add the oil phase to obtain a mixed solution. The homogenization pressure is 25 MPa, and homogenize three times; (S3) Dissolve 0.15 g of carrageenan in 15 L of water preheated to 75℃, stir at 120 rpm for 30 min to obtain a stabilizer solution. Add the stabilizer solution to the mixed solution, mix well, add water to make up to 135 L, mix again, and homogenize. The homogenization pressure is 20 MPa, and homogenize twice to obtain a composition for preventing and improving Alzheimer's disease.

[0034] The resulting composition has a uniform color, is pale yellow, and has a fine, uniform, and stable texture.

[0035] The composition of Example 1 was degassed, sterilized at 135°C for 5-8 seconds, and then dispensed into aluminum cans and sealed for storage. The cans, along with the packaging, were then sterilized at 121°C for 20 minutes. The product is 135 mL per can. Example 2

[0036] (S1) Add 0.25 kg of phosphatidylserine, 0.06 kg of mono- and diglycerides of fatty acids, 0.06 kg of sucrose fatty acid esters, and 0.40 kg of walnut peptides to 2.70 kg of walnut butter preheated to 40-45℃, mix well, and obtain the oil phase; (S2) Dissolve 4 kg of xylitol, 4 kg of whole milk powder, and 0.20 kg of taurine in 45 L of water, mix well, and homogenize. During homogenization, slowly add the oil phase to obtain a mixed solution, and homogenize. The pressure was 25 MPa, and the homogenization was performed three times; (S3) 0.12 g of carrageenan was dissolved in 15 L of water preheated to 75 °C. After dissolution, 0.03 kg of sodium tripolyphosphate was added, and the mixture was stirred at 120 rpm for 30 min to obtain a stabilizer solution. The stabilizer solution was added to the mixed solution, mixed evenly, and then water was added to make up to 135 L. The mixture was mixed again and homogenized at a pressure of 20 MPa. The homogenization was performed twice to obtain a composition for preventing and improving Alzheimer's disease.

[0037] The resulting composition has a uniform color, is pale yellow, and has a fine, uniform, and stable texture.

[0038] The composition of Example 2 was degassed, sterilized at 135°C for 5-8 seconds, and then dispensed into aluminum cans and sealed for storage. The cans, along with the packaging, were then sterilized at 121°C for 20 minutes. The product is 135 mL per can. Example 3

[0039] (S1) Add 0.21 kg of phosphatidylserine, 0.06 kg of mono- and diglycerides of fatty acids, 0.06 kg of sucrose fatty acid esters, and 0.42 kg of walnut peptides to 2.70 kg of walnut butter preheated to 40-45℃, mix well, and obtain the oil phase; (S2) Dissolve 4 kg of xylitol, 4 kg of whole milk powder, and 0.21 kg of taurine in 45 L of water, mix well, and homogenize. During homogenization, slowly add the oil phase to obtain a mixed solution, and homogenize. The pressure was 25 MPa, and the homogenization was performed three times; (S3) 0.12 g of carrageenan was dissolved in 15 L of water preheated to 75 °C. After dissolution, 0.03 kg of sodium tripolyphosphate was added, and the mixture was stirred at 120 rpm for 30 min to obtain a stabilizer solution. The stabilizer solution was added to the mixed solution, mixed evenly, and then water was added to make up to 135 L. The mixture was mixed again and homogenized at a pressure of 20 MPa. The homogenization was performed twice to obtain a composition for preventing and improving Alzheimer's disease.

[0040] The resulting composition has a uniform color, is pale yellow, and has a fine, uniform, and stable texture.

[0041] The composition of Example 3 was degassed, sterilized at 135°C for 5-8 seconds, and then dispensed into aluminum cans and sealed for storage. The cans, along with the packaging, were then sterilized at 121°C for 20 minutes. The product is 135 mL per can. Comparative Example 1

[0042] 0.21 kg of phosphatidylserine, 0.06 kg of mono- and diglycerides of fatty acids, 0.06 kg of sucrose fatty acid esters, 0.42 kg of walnut peptides, 2.70 kg of walnut paste, 4 kg of xylitol, 4 kg of whole milk powder, 0.03 kg of sodium tripolyphosphate, and 0.12 kg of carrageenan were dissolved in 45 L of water. After mixing evenly, water was added to make up to 135 L. After mixing evenly, the mixture was homogenized twice to obtain the composition of Comparative Example 1.

[0043] The resulting composition is brownish-yellow, cloudy, and has flocculent precipitate.

[0044] The composition of Comparative Example 1 was degassed, sterilized at 135°C for 5-8 seconds, and then dispensed into aluminum cans and sealed for storage. The cans, along with their packaging, were then sterilized at 121°C for 20 minutes. The product is 135 mL per can. Stability investigation under acceleration conditions in Experiment Example 1

[0045] The compositions prepared in Examples 1-3 and Comparative Example 1 of this invention were placed at a high temperature of 37.5°C for 6 months. Samples were taken at month 0, month 1, month 2, and month 3, respectively, and centrifuged at 4000 r / min for 15 min. The samples before and after centrifugation were diluted 2000 times. The absorbance of the diluted sample of Comparative Example 3 was used as a blank solution, and the absorbance was measured at a wavelength of 280 nm. The stability constant was calculated using K. e express.

[0046] K e =∣A0-A∣ / A0×100%.

[0047] Where A0 is the absorbance of the uncentrifuged diluted composition, and A is the absorbance of the centrifuged diluted composition.

[0048] The results are shown in Table 1 below.

[0049] Table 1. Stability constant K of the compositions prepared in Examples 1-3 and Comparative Example 1 at 37.5°C. e (100%).

[0050] Group Month 0 Month 1 2nd month 3rd month Example 1 0.62% 2.25% 4.06% 6.44% Example 2 0.70% 2.32% 4.18% 6.07% Example 3 0.68% 2.05% 3.84% 5.99% Comparative Example 1 10.81% 12.72% 14.74% 17.50% As can be seen from Table 1, the stability constants of Examples 1-3 in the third month meet the quality standard requirement K for the emulsion. e The value was 5-10%. In Comparative Example 1, each component was directly added to water and homogenized. The stability constant was greater than 10% in the 0th month, which did not meet the quality standard requirements for emulsions. The emulsion composition was prone to turbidity and had poor stability. Experiment Example 2: Storage Stability Test of Phosphatidylserine in the Product

[0051] The compositions prepared in Examples 1-3 and Comparative Example 1 of this invention were placed at a high temperature of 37.5°C for 6 months. At each of the 0-6 months, 10.0 g of each composition from Examples 1-3 and Comparative Example 1 was taken, 10 ml of chloroform was added, and the mixture was extracted by ultrasonic oscillation. The supernatant was collected by centrifugation and filtered through a 0.45 µm filter membrane. The injection volume was 10 µl, and separation and determination were performed using high-performance liquid chromatography (HPLC). Samples were taken every month. The chromatographic column used was a TOSO7147TSKgel silica-60 (4.6 mm ID × 25 cm). The mobile phase was a 900 / 95 / 5 (v / v) acetonitrile / methanol / phosphoric acid mixture, filtered through a 0.45 µm filter membrane. The mobile phase flow rate was 1 ml / min. The column oven temperature was 35°C. The retention rate of phosphatidylserine was calculated.

[0052] Phosphatidylserine retention rate % = (Concentration of phosphatidylserine / Concentration of phosphatidylserine in month 0) × 100 The results are shown in Table 2 below.

[0053] Table 2 shows the retention rate of phosphatidylserine in Examples 1-3 and Comparative Example 1 of the present invention.

[0054] Group October January February March April May June Example 1 100% 99.45% 99.02% 98.52% 97.88% 97.35% 96.83% Example 2 100% 99.37% 98.81% 98.43% 97.92% 97.44% 97.13% Example 3 100% 99.53% 99.05% 98.56% 98.08% 97.54% 97.02% Comparative Example 1 100% 97.35% 95.59% 94.13% 92.87% 91.22% 89.17% As shown in Table 2, the phosphatidylserine in the compositions prepared in Examples 1-3 for preventing and improving Alzheimer's disease exhibits stable quality, with minimal oxidative degradation and rancidity during storage. The composition prepared by direct mixing and homogenization in Comparative Example 1 shows a lower retention rate of phosphatidylserine compared to Examples 1-3. This indicates that the preparation process of this invention first mixes phosphatidylserine with walnut paste, and the antioxidants in the walnut paste can prevent the oxidation of phosphatidylserine. Experiment Example 3: Morris Water Maze Test in Rats

[0055] Ninety 12-week-old adult SD rats (250±20g), half male and half female, were randomly divided into 9 groups of 10 rats each: normal control group, model group, Example 1 group, Example 2 group, Example 3 group, and comparative example 1 group. They were housed in an SPF-grade constant-temperature, clean, and well-ventilated animal room at a temperature of 23±2℃ and humidity of 35-50%, with free access to water and 12 hours of light per day.

[0056] An Alzheimer's disease rat model was established using 80 rats other than the normal control group. Rats were subcutaneously injected in the neck and back with 45 mg / kg sodium nitrite and 120 mg / kg D-galactose once daily for 6 weeks until they exhibited dementia. Increased spontaneous activities such as scratching the ears and cheeks, and the appearance of dementia symptoms, were considered successful Alzheimer's disease modeling. All 80 rats successfully developed the model.

[0057] Rats in Examples 1-3 and Comparative Example 1 were administered the compositions prepared in Examples 1-3 and Comparative Example 1 by gavage once daily at a dose of 2 mL / kg. Rats in the normal control group and model group were administered the same dose of physiological saline solution by gavage.

[0058] The experimental setup consisted of a circular pool filled with water, 1.5m in diameter and approximately 0.6m deep. The pool was divided into four quadrants. A white platform, approximately 11cm in diameter, was placed in one quadrant, 1cm above the water surface. The room temperature was 25℃, and the water temperature was 20-22℃. Milk powder was added to the water to make it opaque. The location of the water maze within the laboratory was fixed, as were the positions of the objects around the pool and the camera above it.

[0059] After 30 days of continuous drug administration, rats in each group were trained for 5 consecutive days, four times a day with 60-minute intervals between each session. The training involved training the rats to climb onto a safe platform from the water. If a rat failed to climb onto the platform within 60 seconds, it was manually guided to the platform for 5 seconds to memorize its location. Regardless of whether the rat found the platform, it was required to remain on it for 10 seconds. The location of the underwater hidden platform remained unchanged throughout the training process.

[0060] On day 36 of continuous drug administration, which is 5 days after continuous training, rats were placed in the quadrant opposite to the platform, and the time it took for the rats to reach the safe platform was recorded. The underwater hidden platform was then removed, and rats were placed in the quadrant opposite to the platform. The number of times the rats passed the original platform, the number of times they passed the target quadrant, the time they first reached the original platform, and the time they spent in the target quadrant were recorded within 60 seconds. The interval between the two experiments was 60 minutes. The results are shown in Table 3.

[0061] Table 3. Data from the rat spatial exploration experiment.

[0062] Group Escape latency (s) in rats Duration in the original platform quadrant (s) Number of times the original platform was crossed (times) Example 1 Group 14.41±3.16 16.14±2.47 4.1±1.1 Example 2 group 14.12±2.42 16.64±3.00 4.2±1.2 Example 3 Group 13.17±2.47 16.10±2.91 4.1±1.1 Comparative Example 1 15.67±2.91 14.11±1.37 3.4±1.6 Model group 42.11±6.10 9.80±1.80 1.8±1.2 normal control group 12.93±2.55 19.43±3.21 4.8±2.2 As shown in Table 3, the escape latency, time spent in the platform quadrant, and number of platform crossings of rats in Examples 1-3 were similar to those of the normal control group, but significantly different from those of the model group. The data from Comparative Example 1 were similar to those from Examples 1-3, indicating that the presence of flocculent precipitate in the product had little impact on the activity of the composition.

[0063] Experiment 3: Determination of BACE1 protein expression, β-amyloid precursor, and β-amyloid 1-42 in rat hippocampus. After the experiment, the animals were euthanized, and brain tissue was quickly removed. The hippocampus was isolated, and a 10% homogenate was prepared with physiological saline. The homogenate was centrifuged at 10,000 r / min for 5 min at 4℃. The supernatant was collected, and the contents of APP (β-amyloid precursor) and Aβ1-42 (β-amyloid 1-42) were determined by ELISA. The supernatant was then collected, and the expression of BACE1 protein was detected using a rat β-amyloid precursor protein lyase 1 (BACE1) assay kit.

[0064] The results are shown in Table 4.

[0065] Table 4. Content of APP and Aβ1-42 and expression of BACE1 protein in hippocampal tissue of rats in each group.

[0066] Group APP (pg / mg) Aβ1-42 (pg / mg) BACE1 protein expression Example 1 Group 42.53±6.6 85.32±14.08 8.46±0.94 Example 2 group 41.72±7.78 87.21±15.38 8.30±1.09 Example 3 Group 42.25±6.08 83.04±12.3 8.45±0.96 Comparative Example 1 43.88±7.60 88.23±12.73 8.45±0.93 Model group 87.17±13.78 140.99±21.30 19.62±2.35 normal control group 36.60±5.57 71.29±12.11 6.52±0.96 As shown in Table 4, compared with the normal control group, the expression of APP, Aβ1-42, and BACE1 proteins in the hippocampus of rats in the model group showed significant differences. Compared with the model group, the APP content, Aβ1-42 content, and BACE1 protein expression in the hippocampus of rats in Examples 1-3 showed significant differences. Compared with the normal control group, the APP content in Example 2 showed a statistically significant difference. This indicates that the treatment effect of Examples 1-3 groups was significant. Compared with Examples 1-3 groups, the expression of Aβ1-42 and BACE1 proteins in the hippocampus of rats in Comparative Example 1 group showed significant differences. P There were no significant differences in P content, Aβ1-42 content, and BACE1 protein expression.

[0067] The embodiments of the present invention have been described in detail above, but the content described is only a preferred embodiment of the present invention and should not be considered as limiting the scope of the present invention. All equivalent changes and improvements made within the scope of the present invention should still fall within the patent coverage of the present invention.

Claims

1. A method for preparing a composition for preventing and improving Alzheimer's disease, characterized in that: Includes the following steps: (S1) Add 0.2-0.25 kg of phosphatidylserine, 0.12 kg of emulsifier and 0.40-0.45 kg of walnut peptide to 2.70 kg of walnut paste preheated to 40-45℃, mix well to obtain the oil phase; (S2) Dissolve 4 kg of xylitol, 4 kg of whole milk powder and 0.20-0.25 kg of taurine in 45 L of water, mix well and homogenize. During the homogenization process, slowly add the oil phase to obtain a mixed solution. (S3) Dissolve 0.15g of stabilizer in 15L of water preheated to 75°C to obtain a stabilizer solution, wherein the stabilizer includes carrageenan. Add the stabilizer solution to the mixed solution, add water to make up to 135L, mix well and homogenize to obtain a composition for preventing and improving Alzheimer's disease.

2. The method for preparing the composition for preventing and improving Alzheimer's disease according to claim 1, characterized in that: The stabilizer also includes sodium tripolyphosphate, wherein the weight ratio of sodium tripolyphosphate to carrageenan in the stabilizer is 1:

4.

3. The method for preparing the composition for preventing and improving Alzheimer's disease according to claim 2, characterized in that: In step (S3), 0.12 kg of carrageenan is dissolved in 15 L of water preheated to 75 °C. After dissolution, 0.03 kg of sodium tripolyphosphate is added and stirred until homogeneous to obtain a stabilizer solution.

4. The method for preparing the composition for preventing and improving Alzheimer's disease according to claim 3, characterized in that: (S3) The stabilizer dissolves in 30-40 minutes at a stirring speed of 120 rpm.

5. The method for preparing the composition for preventing and improving Alzheimer's disease according to claim 4, characterized in that: (S1) The emulsifier includes mono-, mono-, and diglycerides of fatty acids and sucrose fatty acid esters, with a weight ratio of 1:

1.

6. The method for preparing the composition for preventing and improving Alzheimer's disease according to claim 5, characterized in that: In (S1), a high-shear emulsifier is used for mixing, with a stirring speed of 5000-8000 rpm and a stirring time of 10-15 min.

7. The method for preparing the composition for preventing and improving Alzheimer's disease according to claim 6, characterized in that: (S2) The homogenization pressure is 25 MPa, and homogenization is performed three times. (S3) The homogenization pressure is 20 MPa, and homogenization is performed twice.

8. The method for preparing the composition for preventing and improving Alzheimer's disease according to claim 7, characterized in that: Includes the following steps: (S1) Add 0.21 kg of phosphatidylserine, 0.12 kg of emulsifier and 0.42 kg of walnut peptide to 2.70 kg of walnut paste preheated to 40-45℃, mix well to obtain the oil phase; (S2) Dissolve 4 kg of xylitol, 4 kg of whole milk powder and 0.21 kg of taurine in 45 L of water, mix well and homogenize. During the homogenization process, slowly add the oil phase to obtain a mixed solution. (S3) Dissolve 0.03 kg of sodium tripolyphosphate and 0.12 kg of carrageenan in 15 L of water preheated to 75 °C to obtain a stabilizer solution. Add the stabilizer solution to the mixed solution, add water to make up to 135 L, mix again and homogenize to obtain a composition for preventing and improving Alzheimer's disease.

9. A composition for preventing and improving Alzheimer's disease, characterized in that: It is prepared by the preparation method according to any one of claims 1-8.

10. The use of the composition for preventing and improving Alzheimer's disease according to any one of claims 1-8 in the preparation of food or medicine for Alzheimer's disease.

Images